Pharma ETFs in Focus on Trump's Drug Price Overhaul
Trump's plan to slash the price of prescription drugs by 30% put pharma ETFs in focus.
Prediction & Performance
LLY
PryogiTM predictions explained
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter explained
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart explained
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
Eli Lilly and Company(LLY) news
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Mark Cuban Challenges Charlie Kirk's Take On Big Pharma, Highlights Role Of PBMs In Drug Price Surge: 'For Your Company…Ask Your PBM For A List Of Claims' - Johnson & Johnson ( NYSE:JNJ ) , Eli Lilly ( NYSE:LLY )
Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers ( PBMs ) are the main culprits, not Big Pharma.
Billionaire Chase Coleman Has 68% of His $24.5 Billion Portfolio Invested in 10 Stocks. Here's the Best of the Bunch.
At age 49, Chase Coleman III is relatively young to be one of the wealthiest people on the planet. But his net worth of $6 billion landed him at No. 581 on Forbes' 2025 ranking of the world's billionaires. Coleman manages even more money than that $6 billion figure.
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial - Novo Nordisk ( NYSE:NVO ) , Eli Lilly ( NYSE:LLY )
Eli Lilly and Company's LLY Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S's NVO Wegovy in a 72-week head-to-head trial.
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency' - iShares U.S. Pharmaceutical ETF ( ARCA:IHE ) , Johnson & Johnson ( NYSE:JNJ )
On Sunday, President Donald Trump vowed to slash prescription drug prices through a sweeping executive order. What Happened: Trump took to Truth Social and announced plans to sign a new executive order.
President Trump Just Announced Terrible News for Eli Lilly Investors
President Donald Trump's second term in office has been challenging for investors, at least so far. Trump imposed sweeping tariffs on imports from most countries worldwide. For now, several industries have escaped these trade policies, including pharmaceuticals.
Prediction: These 2 Stocks Will Join the Trillion-Dollar Club by 2030
There is a small, exclusive group of companies with market caps above $1 trillion. Over time, more corporations will join this elite club. However, joining this clique is just one ( albeit an impressive ) milestone. Investors want to find companies that can perform well over the long run, even ...
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation - Eli Lilly ( NYSE:LLY )
INDIANAPOLIS and WEST LAFAYETTE, Ind., May 9, 2025 /PRNewswire/ -- Eli Lilly and Company LLY and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years.
4 No-Brainer Stocks to Buy Right Now
Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time. However, even in the current environment, there are excellent investment opportunities. Those who go shopping for great stocks right now and hold on to them for a while should see excellent ...
One of the Largest Teacher Pension Funds in the U.S. Sold Nvidia, Tesla, and Apple and Piled Into a Popular Pharmaceutical Stock Up 395% Over the Last 5 Years
With the second quarter of 2025 now over a month old, many investment funds will soon begin disclosing what stocks they held at the end of the first quarter, essentially providing investors a glimpse of what they bought and sold.
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks 3 Pharma ETFs To Watch As Trump Turns Up The Heat On Drugmakers - AstraZeneca ( NASDAQ:AZN ) , iShares U.S. Pharmaceutical ETF ( ARCA:IHE )
Trump's push to tie Medicaid drug prices to lower international benchmarks could erase $1 trillion in revenues over 10 years. Don't miss this list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on.
A Look at Pharma ETFs After Strong Q1 Earnings
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
Post-Earnings Dip: Why This Beaten-Down Stock Is a No-Brainer Buy
There is plenty of movement in equity markets during earnings season, but from a fundamental standpoint, investment theses seldom change. That's why significant price drops in shares of quality businesses can be excellent buying opportunities.That brings us to Eli Lilly ( NYSE: LLY ) , a leading ...
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?
For a while, it seemed as if Eli Lilly ( NYSE: LLY ) could do no wrong. Its shares skyrocketed. The company's market cap grew so much that it was within striking distance of the $1 trillion mark. Along the way, Lilly became the largest healthcare company in the world based on market cap.However, ...
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity - Novo Nordisk ( NYSE:NVO ) , Eli Lilly ( NYSE:LLY )
Novo Nordisk A/S NVO is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and efficacy figures that are similar to its injectables.
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook - Novo Nordisk ( NYSE:NVO )
Q1 Wegovy sales rose 85% to DKK 17.36 billion; Ozempic up 18% to DKK 32.72 billion. Novo Nordisk's Q1 sales hit $10.89 billion, missing the $11.64 billion consensus estimate. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds ...
Despite Bruce Galloway's Pushback On Bankruptcy, WeightWatchers Enters Chapter 11; Says Members Won't Be Affected - Novo Nordisk ( NYSE:NVO ) , Eli Lilly ( NYSE:LLY )
Once a dominant force in the weight-loss industry, WW International Inc. WW, formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now staring at a bankruptcy process to reorganize its finances.
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight - Becton Dickinson ( NYSE:BDX ) , Bristol-Myers Squibb ( NYSE:BMY )
FDA conducts 12K domestic inspections yearly, but only 3K abroad-foreign sites flagged for serious issues over twice as often. Johnson & Johnson, Roche, and Novartis plan over $128 billion in combined U.S. investments over the next five years.
Eli Lilly Stock Is Sliding Tuesday: What's Going On? - Eli Lilly ( NYSE:LLY )
President Donald Trump signed a new executive order aimed at boosting domestic drug manufacturing. The executive order comes ahead of the Trump administration's planned tariffs on pharmaceuticals imports. Feel unsure about the market's next move?
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
Good news for Hims & Hers stock spooks Lilly and Novo investors.
Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?
Shares of Eli Lilly ( NYSE: LLY ) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. However, the guidance reduction stems from an up-front payment it made to acquire Scorpion Therapeutics' STX-478 program to ...
Eli Lilly and Company(LLY) news
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns - iShares Biotechnology ETF ( NASDAQ:IBB ) , AbbVie ( NYSE:ABBV )
President Donald Trump signed an executive order Monday directing the Food and Drug Administration to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks
Investors Heavily Search Eli Lilly and Company ( LLY ) : Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?
Investors may stay invested in PFE stock to see how its new growth drivers perform.
3 No-Brainer Stocks to Buy in May
Any time is a great time to buy stocks -- if you pick the right stocks. That's true even in May, a month where some investors have traditionally opted to take a break from the stock market for the summer.Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May.
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Stock market volatility or even economic downturns usually don't affect drugmakers' underlying businesses much, if at all.
Bulls And Bears: Lilly, Microsoft, Starbucks - And Markets Fully Recover Tariff Chaos Losses - Apple ( NASDAQ:AAPL ) , AbbVie ( NYSE:ABBV )
Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories. U.S. markets rebounded this week, fully recovering losses incurred since President Donald Trump's April 2 tariff escalation.
Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say - Eli Lilly ( NYSE:LLY )
Goldman Sachs cuts Eli Lilly's price target to $883, citing PBM-related uncertainty after CVS dropped Zepbound. BofA keeps $1,000 price target, saying Zepbound remains superior and CVS move is not a major negative trend. Feel unsure about the market's next move?
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.
Eli Lilly's Options Frenzy: What You Need to Know - Eli Lilly ( NYSE:LLY )
Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 30 unusual trades. Delving into the details, we found 50% of traders were bullish, while 33% showed bearish tendencies.
Is Novo Nordisk Stock a Buy?
For years, Denmark-based Novo Nordisk ( NYSE: NVO ) was a fairly traditional develop-and-market pharmaceutical company that escaped notice by many investors. Though listed on American stock exchanges, it didn't distinguish itself much in the vast sea that is the domestic biotech and ...
Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday? - Apple ( NASDAQ:AAPL )
S&P 500 heads for eighth straight gain, fully recovering post-tariff losses; Nasdaq 100 leads with strong tech earnings. Microsoft and Meta surge after earnings; Eli Lilly sinks 10% on 2025 guidance cut. Today's manic market swings are creating the perfect setup for Matt's next volatility trade.
Why Eli Lilly Stock Is Sinking Today
Shares of Eli Lilly ( NYSE: LLY ) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as the S&P 500 ( SNPINDEX: ^GSPC ) gained 1% and the Nasdaq Composite ( NASDAQINDEX: ^IXIC ) gained 1.9%.The pharmaceutical giant released earnings that disappointed investors ...
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates. Stock declines.
Initial Claims More Than Expectations
Pre-market futures are up this morning, though somewhat muted from levels prior to economic reports out this morning on unemployment claims.
Jobless Claims Higher; Q1 Earnings from LLY, MCD & More
Last week, 241K Americans filed for unemployment on Initial Jobless Claims, with Continuing Claims touching 1.9 million.
Mounjaro Maker Eli Lilly Clocks 45% Jump In Q1 Revenue, Cuts 2025 Profit Outlook But Not Due To Tariffs - Eli Lilly ( NYSE:LLY )
Eli Lilly Q1 revenue rose 45% to $12.73 billion; Mounjaro sales surged 113% to $3.84 billion, Zepbound hit $2.31 billion. 2025 EPS forecast cut to $20.78-$22.28 from $22.50-$24.00 due to $1.57 billion in IPR&D charges.
Eli Lilly ( LLY ) Q1 Earnings Lag Estimates
Lilly (LLY) delivered earnings and revenue surprises of -5.11% and 0.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
US Stock Futures Rise As Meta, Microsoft Earnings Fuel Optimism: GDP Slump Linked To Tariff Anticipation, Not Recession, Says Analyst - Apple ( NASDAQ:AAPL ) , Airbnb ( NASDAQ:ABNB )
U.S. stock futures climbed early Thursday, buoyed by strong earnings reports from two of the "Magnificent 7" companies after Wednesday's market close. While markets were rattled by the Commerce Department's report of a 0.3% GDP contraction, major indexes rebounded and ended the previous session ...
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Eli Lilly ( NYSE:LLY )
Eli Lilly and Company LLY will release earnings results for the first quarter, before the opening bell on Thursday, May 1. Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $3.46 per share, up from $2.58 per share in the year-ago period.
Buy Hims ( HIMS ) or Novo Nordisk ( NVO ) Stock After Partnership Announcement?
Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals? - Eli Lilly ( NYSE:LLY )
Eli Lilly stock trades above all major moving averages, indicating a strongly bullish technical trend. Analysts see 3% upside, but momentum indicators suggest the rally could have more room to run. Feel unsure about the market's next move?
Price Over Earnings Overview: Eli Lilly - Eli Lilly ( NYSE:LLY )
In the current session, the stock is trading at $893.76, after a 0.97% increase. Over the past month, Eli Lilly Inc. LLY stock increased by 9.23%, and in the past year, by 18.24%.
Market Whales and Their Recent Bets on LLY Options - Eli Lilly ( NYSE:LLY )
Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 33 trades. If we consider the specifics of each trade, it is accurate to state that 39% of the investors opened trades with bullish expectations and ...
Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More
Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( NYSE: LLY ) . It is the most valuable healthcare company in the world, with a market cap of around $800 billion.